Deutsche Hypothekenbank (Actien-Gesellschaft)

  • WKN: 804200
  • ISIN: DE0008042003
  • Land: Deutschland

Nachricht vom 22.08.2019 | 20:24

Deutsche Hypothekenbank (Actien-Gesellschaft): Implementing the planned capital measures at NORD/LB will only be possible in the 4th quarter of 2019

Deutsche Hypothekenbank (Actien-Gesellschaft) / Key word(s): Corporate Action/Miscellaneous
Deutsche Hypothekenbank (Actien-Gesellschaft): Implementing the planned capital measures at NORD/LB will only be possible in the 4th quarter of 2019

22-Aug-2019 / 20:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Deutsche Hypothekenbank (Actien-Gesellschaft) is a wholly-owned subsidiary of Norddeutsche Landesbank - Girozentrale ("NORD/LB") and is closely linked to its parent company by a control and profit and loss transfer agreement and a waiver rule in accordance with Art. 7 (1) CRR and Section 2a (1) of the German Banking Act (KWG). On 22 August 2019 NORD/LB published the following ad hoc announcement:

"Norddeutsche Landesbank Girozentrale ("NORD/LB"), its owners - the state of Lower Saxony, the state of Saxony-Anhalt (together, the "States"), the Savings Banks Association of Lower Saxony (Sparkassenverband Niedersachsen) and the Savings Banks Holding Association in Saxony-Anhalt (Sparkassenbeteiligungsverband Sachsen-Anhalt) and the Special Purpose Holding Association of the Savings Banks in Mecklenburg-Western Pomerania (Sparkassenbeteiligungszweckverband Mecklenburg-Vorpommern) (together with the States, the "Owners") - as well as the Savings Banks Finance Group (Sparkassenfinanzgruppe) have reached agreement on all material points regarding the bank's realignment and the implementation of the planned capital measures. In this context, NORD/LB, its Owners and the Savings Banks Finance Group are in close contact with the relevant supervisory authorities and the EU Commission on an ongoing basis.

In the course of these consultations with the relevant supervisory authorities it became clear today that, due to the complexity of the proceedings and mutual interdependencies, due to the necessity of consent by the EU Commission, which has not yet been granted, due to the necessity of parlamentary proceedings in the States and also due to the steps required with respect to the regulatory proceedings, the implementation of the capital measures previously envisaged for the 3rd quarter of 2019 may only be effected in the 4th quarter of 2019.

NORD/LB is in close contact with the relevant supervisory authorities on an ongoing basis also with respect to this adjustment of the previous timing and the resulting delay in implementing the capital measures.

On this basis, taking into account the continuous progress made in the overall process of realigning NORD/LB, NORD/LB's Management Board expects that the capital injection and the implementation of further capital measures will be effected in the 4th quarter of 2019.
By implementing these capital strengthening and realignment measures, the capital ratios of NORD/LB currently failing to meet the regulatory minimum requirements will significantly increase and comply with all regulatory requirements."

A complete overview of outstanding securities issued by Deutsche Hypothekenbank (Actien-Gesellschaft) is available at the website of Deutsche Hypothekenbank (Actien-Gesellschaft) - at: https://www.deutsche-hypo.de/en/finanzinstrumente

 

22-Aug-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktuelle Research-Studie

Original-Research: Rapid Dose Therapeutics Corp. (von Sphene Capital GmbH): Buy Rapid Dose Therapeutics Corp.

15. Oktober 2019